Lilly Set to Pay $14 per Share in $1.2B Ventyx Acquisition
Under the agreement, Eli Lilly will acquire all outstanding shares of Ventyx for $14 per share in an all-cash transaction valuing the biopharma at approximately $1.2 billion. The offer represents a 62% premium to Ventyx’s 30-day VWAP and is expected to close in H1 2026, pending shareholder and regulatory approvals.
1. Definitive Agreement for Lilly Acquisition
On January 7, 2026, Eli Lilly & Company entered into a definitive agreement to acquire Ventyx Biosciences in an all-cash transaction valued at approximately $1.2 billion. Under the terms, Ventyx stockholders will receive $14.00 per share, representing a premium of roughly 62% to the 30-day volume-weighted average trading price ended January 5, 2026. The deal, approved by the boards of both companies, is not subject to financing conditions and is expected to close in the first half of 2026, pending customary regulatory approvals and shareholder consent.
2. Ventyx Clinical Pipeline Highlights
Ventyx’s pipeline focuses on small-molecule NLRP3 inhibitors targeting inflammation across cardiometabolic, neurodegenerative and autoimmune indications. Lead candidate VTX2735 is in Phase 2 trials for recurrent pericarditis, while VTX3232, a CNS-penetrant NLRP3 inhibitor, showed significant reductions in cardiovascular risk biomarkers in its recent Phase 2 study and has completed a biomarker trial in early Parkinson’s disease. The company also has two Phase 2 assets for inflammatory bowel disease: tamuzimod (VTX002), an S1P1 receptor modulator, and VTX958, a TYK2 inhibitor.
3. Stock Market Reaction
Following reports of acquisition talks, Ventyx shares surged 62.59% in after-hours trading, reflecting investor enthusiasm for the company’s differentiated oral inflammation platform. Trading volume spiked to more than ten times the ten-day average, underscoring heightened interest from both institutional and retail participants ahead of the formal merger announcement.
4. Strategic Rationale and Investor Implications
Lilly’s acquisition of Ventyx bolsters its inflammatory-mediated disease portfolio, complementing existing programs in cardiometabolic health, neurodegeneration and autoimmunity. For investors, the deal secures near-term value realization at a substantial premium and provides exposure to Ventyx’s clinical milestones, including upcoming Phase 2 readouts. Additionally, backing from Lilly’s R&D infrastructure and global commercialization capabilities enhances the likelihood of successful late-stage development and eventual market launch.